On June 1, another pharmaceutical executive announced his departure.
Kai Laiying issued an announcement that it had received a written resignation report from independent director Mr. Pan Guangcheng, and due to personal reasons, Mr. Pan Guangcheng applied to resign as an independent director, a member of the Strategy Committee and a member of the Nomination Committee of the Company, and would no longer hold any position in the Company after resignation.
The changes in personnel in the pharmaceutical circle have been non-stop. Just this past May, there were personnel changes in the top management of 14 pharmaceutical companies:
<h1 class="pgc-h-arrow-right" data-track="8" Personnel changes > May</h1>
Hanhui Pharmaceutical: The CEO and CFO have changed
On May 31, Hanhui Pharmaceutical announced major organizational restructuring and personnel appointments, and since June 1, Li Yan has stepped down as ceo of Hanhui Pharmaceutical and has been succeeded by Hu Zhiqiang, reporting to Liu Qi, chairman of the company.
In addition, Yu Tieming will step down as the company's chief financial officer, and Li Hao will take over, appointing He Dong as vice president of the national business and diversification business department, all of which are directly reported to Hu Zhiqiang, the new CEO of Hanhui Pharmaceutical.
Luyan Pharmaceutical: Deputy general manager resigned
On May 28, Luyan Pharmaceutical issued an announcement that Mr. Zhao Zhongming submitted his resignation as deputy general manager of the company for personal reasons, and after his resignation, Mr. Zhao Zhongming no longer held any other position in the company except for continuing to serve as the director of Fujian Kangyuan Image Intelligence Research Institute and Guangzhou Kangyuan Image Intelligence Research Institute, a non-profit organization initiated by the company.
Hao Oubo: The director resigns
On May 24, Jiangsu Haooubo Biopharma issued an announcement that Ms. Li Shuhong resigned as a director, secretary of the board of directors and chief financial officer for personal reasons, and will not hold any position in the company after resignation.
In addition, the Board of Directors agreed to appoint Mr. Wang Kai, a director and deputy general manager of the Company, as the secretary of the Board of Directors of the Company for a term from the date of deliberation and approval of the Current Board of Directors to the expiration of the term of office of the second Board of Directors.
Sinopharm Unanimous: Dismissed the deputy general manager of the company
On May 21, Sinopharm unanimously issued an announcement that the board of directors agreed to dismiss Mr. Zhao Xiaochuan as the deputy general manager of Sinopharm. After the dismissal, Mr. Zhao Xiaochuan still serves as the chairman of the board of directors of Sinopharm Holdings Guoda Pharmacy Co., Ltd., a subsidiary of Sinopharm Holdings.
East Ejiao: Senior Vice President resigns
On May 21, Dong'e Ejiao announced that due to personal reasons, Mr. Wu Huaifeng applied to resign as senior vice president of the company and no longer held other positions in the company.
Sunshine Guojian: Resignation of independent directors
On May 21, 3Sbio Guojian Pharmaceutical announced that Mr. Ma Guoqiang applied for resignation as an independent director of the third board of directors of the company and the corresponding position of the special committee set up under the board of directors due to health reasons, and will no longer hold any position in the company after resignation.
Nanjing Pharmaceutical: Resignation of director
On May 21, the Board of Directors of Nanjing Pharmaceutical received a written resignation report submitted by Mr. Richard Joseph Anthony Gorsuch, a director of the Company, who applied to resign as a director of the eighth board of directors, the nomination and human resources planning committee of the board of directors, and the remuneration and performance appraisal committee of the company due to other work arrangements, and did not hold any position in the company.
The head of finance of Jiuzhou Pharmaceutical resigned
On May 18, Zhejiang Jiuzhou Pharmaceutical issued an announcement that Mr. Dai Yunyou resigned as the head of finance for personal reasons and will continue to serve in the audit department of the company after resignation.
In addition, the company held the seventh meeting of the seventh board of directors on the same day and agreed to appoint Mr. Sha Yujie as the head of the company's finance.
Hebang Biotech: Deputy General Manager retires and leaves
On May 18, Sichuan Hebang Biotech issued an announcement that Mr. Wang Yaxi applied to resign as deputy general manager of the company due to his retirement at an old age, and would no longer hold any position in the company after resignation.
Jinling Pharmaceutical: Employee supervisor resigns
On May 17, Jinling Pharmaceutical announced that Ms. Tang Honglan resigned as a staff supervisor of the eighth session of the Board of Supervisors of the Company for personal reasons, and after her resignation, she is still engaged in medical work in Suqian People's Hospital Co., Ltd., a holding subsidiary of the Company.
Lepu Medical: Deputy General Manager resigned
On May 14, Lepu Medical announced that due to work arrangements, Ms. Chen Juan applied to resign as deputy general manager of the company on May 13, and her original term of office expired on January 22, 2023, and will continue to serve as the chairman and general manager of Lepu Xintai Medical Technology (Shanghai) Co., Ltd., a holding subsidiary of the company.
Yibai Pharmaceutical replaced 4 executives
Yibai Pharmaceutical issued an announcement on the evening of May 13 that due to personal reasons, Mr. Tang Deping applied to resign as a director of the company, a member of the strategy committee of the board of directors, a member of the remuneration and appraisal committee and a general manager. After his resignation, Mr. Tang Deping did not hold other positions in the company.
On the same day, due to personal reasons, Mr. Li Gang applied to resign as deputy general manager of the company, Ms. Tian Xiaohong applied to resign as deputy general manager of the company, and Mr. Xia Xiaohui applied to resign as the chief engineer of the company. After resigning, the three remained in other positions at the company.
TEHLONG Pharmaceutical: Independent director resigns at the end of his term of office
On May 7, Henan Tailong Pharmaceutical issued an announcement that Mr. Wang Bo had served as an independent director of the company for six consecutive years, and applied to resign as an independent director of the eighth board of directors of the company and the relevant positions of the special committees under the board of directors.
Nanxin Pharmaceutical: The securities representative leaves
On May 5, Hunan Nanxin Pharmaceutical announced that due to personal reasons, Mr. Liu Feng proposed to resign as the company's securities affairs representative and will no longer hold any position in the company after resignation, and the above resignation report will take effect from the date of delivery to the company's board of directors.
This has a lot to do with the changing market environment. With the deepening of medical reform, the normalization of collection and procurement, and the promotion of policies such as consistency evaluation, enterprises are facing a situation of continuous transformation. Among them, some pharmaceutical companies adjust their product lines, organizational structures, or focus on advantageous areas, or gradually sell business areas that are not strong, so management also makes new choices along with corporate strategic adjustments.
<h1 class="pgc-h-arrow-right" data-track="108" what kind of talents are needed in the pharmaceutical industry >? </h1>
Analyzing Michael Page's "China 2021 Talent Trend Report", the following trends can be summarized:
1. Digital transformation is the development trend of the present and the future for a long time
According to the report, 68% of enterprises plan to increase their investment in technology and digital tools in 2021
2. Clinical, medical and digital and innovation are the 3 hottest sub-areas in the life sciences sector
With the layout of large pharmaceutical companies in the field of tumor treatment, the competition has intensified, and the hot spots in the Chinese market have gradually shifted to drug innovation. The report pointed out that job seekers in the market are also more interested in innovative drugs, new medical and diagnostic-related positions, in addition to salary, but also care about the richness of the product line.
According to the 2021 medical and health industry talent market insight report released by Cree International, it can also see the trend of talent demand in hot sectors of the industry:
1. The structure of pharmaceutical marketing talents has changed
The changes inside and outside the industry in 2020 have accelerated the pace of transformation and innovation in pharmaceutical marketing.
According to the survey, in terms of pharmaceutical marketing talents, the talent demand of foreign enterprises is shrinking, and the talent demand of private enterprises is increasing; the talent gap of foreign enterprises is mainly in regional promotion managers, key account managers, regional managers, regional managers, etc., and the talent gap of private enterprises is mainly in sales directors, regional directors, marketing directors, post-listing medical directors, etc.
2. The demand for Internet medical talents has grown
According to statistics, during the epidemic period, the Internet diagnosis and treatment of hospitals under the national health commission increased by 17 times compared with the same period last year, and the number of diagnosis and treatment consultations on third-party Internet service platforms increased by more than 20 times year-on-year.
The demand for medical Internet talents is increasing, and the ability requirements for talents are gradually increasing. At present, the shortage of talents is mainly marketing positions and technical positions.
Technical talents are mainly in first- and second-tier cities, and marketing positions are distributed throughout the country. The sources of marketing talents are medical Internet companies, pharmaceutical and medical device companies, and technical talents mainly come from various Internet companies.
The above trends illustrate the different directions of the transformation of pharmaceutical companies, and in general, pharmaceutical people need to integrate into the trend faster to be ready for competition.